DRRX earnings call for the period ending June 30, 2020.
News & Analysis: DURECT
Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.
DRRX earnings call for the period ending March 31, 2020.
The biotech becomes a COVID-19 play and benefits from a competitor's failure.
DRRX earnings call for the period ending December 31, 2019.
Seven biotechs led the way.
The biotech's midstage study of DUR-928 failed, but the drug isn't dead yet.
Investors jump in ahead of a binary event.
Hardly anyone's heard of either of these drugmakers, but some analysts think they could be top performers.
Investors bid up the share price after the company received some bullish praise from a Wall Street pro.